• email
  • rss
  • twitter
  • facebook
  • linkedin

Ceapro Inc.

Enabling Technologies

Enabling Technologies

Ceapro's proprietary enabling technologies make us the ideal partner for the identification, extraction, production and processing of unique active ingredients originating from natural sources.

Learn More
Cosmeceuticals

Cosmeceuticals

Ceapro's two value driving products, oat beta glucan and avenanthramides, are manufactured from Ceapro’s proprietary extraction technology and sold either as bulk active ingredients in many household names, cosmetic and personal care brands, (such as Aveeno, Burt’s Bees and Neutrogena) and as high end finished products through our JuventeDC product line.

Learn More
Nutraceuticals

Nutraceuticals

Ceapro is actively developing powder formulations of oat beta glucan and avenanthramides, which have proven health benefits, to expand into this growing market.

Learn More

PGX Technology

PGX technology is a novel spray drying technique for processing water-soluble biopolymers which utilizes the unique and tunable properties of Pressurized Gas eXpanded liquids.

Learn More About PGX
PGX Technology

Stock Information

TSX Venture

CZO

Loading...

Change

Loading...

Volume

Loading...

Day Range

Loading...

52 Week Range

Loading...

CEO Interview

Gilles Gagnon, CEO of Ceapro provides Company overview and discusses how Ceapro is working on commercializing the "active ingredients" derived from oats and other renewable plant resources for healthcare and cosmetic industries.

Corporate Presentation

View our latest corporate presentation to learn more about Ceapro, our products and our proprietary manufacturing technology.

View Presentation
Investor Presentation

Products

Ceapro isolates ingredients from oat products, such as Avenanthramides and Beta Glucan, and botanical products to naturally enhance popular cosmetic and personal care products.

View Our Products
Products

Latest News

Ceapro Inc. Announces Signing of a Contribution Agreement with National Research Council of Canada
Aug 15, 2019 | Read More

Ceapro Announces Results of 2019 Shareholders’ Meeting
Jun 10, 2019 | Read More

Ceapro Presents Positive Results from Avenanthramides Study at the 2019 American Society of Sports Medicine Meeting
Jun 5, 2019 | Read More

Ceapro Inc. Commences Patient Enrollment in First-in-Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
Jun 3, 2019 | Read More

View All News